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Abstract
Background: Friedreich ataxia is an autosomal recessive neurodegenerative disease caused by reduced expression levels of
the frataxin gene (FXN) due to expansion of triplet nucleotide GAA repeats in the first intron of FXN. Augmentation of
frataxin expression levels in affected Friedreich ataxia patient tissues might substantially slow disease progression.
Methodology/Principal Findings: We utilized bioinformatic tools in conjunction with chromatin immunoprecipitation and
electrophoretic mobility shift assays to identify transcription factors that influence transcription of the FXN gene. We found
that the transcription factors SRF and TFAP2 bind directly to FXN promoter sequences. SRF and TFAP2 binding sequences in
the FXN promoter enhanced transcription from luciferase constructs, while mutagenesis of the predicted SRF or TFAP2
binding sites significantly decreased FXN promoter activity. Further analysis demonstrated that robust SRF- and TFAP2-
mediated transcriptional activity was dependent on a regulatory element, located immediately downstream of the first FXN
exon. Finally, over-expression of either SRF or TFAP2 significantly increased frataxin mRNA and protein levels in HEK293
cells, and frataxin mRNA levels were also elevated in SH-SY5Y cells and in Friedreich ataxia patient lymphoblasts transfected
with SRF or TFAP2.
Conclusions/Significance: We identified two transcription factors, SRF and TFAP2, as well as an intronic element
encompassing EGR3-like sequence, that work together to regulate expression of the FXN gene. By providing new
mechanistic insights into the molecular factors influencing frataxin expression, our results should aid in the discovery of new
therapeutic targets for the treatment of Friedreich ataxia.
Citation: Li K, Singh A, Crooks DR, Dai X, Cong Z, et al. (2010) Expression of Human Frataxin Is Regulated by Transcription Factors SRF and TFAP2. PLoS ONE 5(8):
e12286. doi:10.1371/journal.pone.0012286
Editor: Sumitra Deb, Virginia Commonwealth University, United States of America
Received March 27, 2010; Accepted July 24, 2010; Published August 20, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the intramural program of the NICHD, National Institutes of Health, and in part by a research grant from Friedreich Ataxia
Research Alliance (FARA): http://www.curefa.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: likuanyu@nju.edu.cn (KL); trou@helix.nih.gov (TAR)
Introduction
Friedreich’s ataxia, the most common inherited ataxia, is an
autosomal recessive neurodegenerative disease caused by expan-
sion of triplet nucleotide GAA repeats in the first intron of the FXN
gene. Expansion of the GAA region from fewer than 200 to as
many as 1500 repeats results in significant reduction of frataxin
protein levels in affected patient tissues. The exact physiological
function of frataxin continues to be a subject of intense research.
Early reports demonstrated robust mitochondrial iron accumula-
tion in Friedreich ataxia patient cardiac tissue [1], as well as in a
Saccharomyces cerevisiae strain lacking the yeast frataxin homologue
Yfh1p [2]. Additionally, deficiency of iron-sulfur (Fe-S) cluster-
containing mitochondrial respiratory chain enzymes is a feature
found both in patient cardiac biopsies and in Yfh1p-deficient S.
cerevisiae [3]. These seminal findings regarding frataxin function
have led to further work suggesting potential roles for human
frataxin (and its homologues in lower organisms) in cellular
functions including as an iron donor for heme biosynthesis [4], as
an iron storage protein [5], as an iron chaperone [6] or accessory
protein [7] important for Fe-S cluster assembly. Although there is
ongoing debate over the function(s) of frataxin, it seems clear that
its absence in human cells results in impaired Fe-S protein
activities as well as mitochondrial iron overload.
The clinical manifestations of Friedreich ataxia involve
neurodegeneration in the spinal cord and cerebellum, causing
gait disturbances, speech impairment, and increased incidence of
diabetes. Mitochondrial iron deposition in the heart is known to
accompany the hypertrophic cardiomyopathy and eventual heart
failure observed in Friedreich ataxia patients, which commonly
leads to mortality in the third or fourth decade of life (reviewed
elsewhere [8]). Since oxidative tissue damage is thought to result
from mitochondrial iron overload, drug screening studies have
focused on ameliorating cardiac iron accumulation using iron
chelators [9,10], and enhancing respiratory chain function using
coenzyme Q10 and/or reducing oxidative damage with antiox-
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cardiac and neurological outcomes in Friedreich ataxia patients is
under continued evaluation.
A recent study demonstrated an association between the GAA
repeats within the FXN gene and aberrant frataxin pre-mRNA
processing [13], and the authors proposed that binding of
transcribed GAA repeats to nuclear splicing factors can interfere
with turnover of intronic RNA and lead to decreased abundance
of mature mRNA [13]. However, accumulating evidence indicates
that epigenetic changes caused by heterochromatin formation in
the promoter region and/or the first intron of the FXN gene also
contribute to the dramatic reduction of frataxin protein levels in
Friedreich ataxia patients. Decreased histone acetylation and
extensive methylation of CpG regions upstream of the GAA repeat
are observed in Friedreich ataxia patient cell lines and tissues
[14,15], suggesting that enhanced heterochromatin formation
might impede the transcription of frataxin, leading to lower
frataxin protein levels [14,16,17]. Recently, a study employing an
experimental histone deacetylase (HDAC) inhibitor in a mouse
model of Friedreich ataxia revealed that this drug can substantially
increase frataxin mRNA and protein levels [16]. Reduction of
frataxin transcription very likely results from reduced accessibility
of transcriptional regulatory factors to the promoter region and/or
trinucleotide repeat region [15,18,19,20]. However, the identity
and number of the regulatory factors influencing frataxin
expression are largely unknown. Thus, in-depth investigation of
the transcriptional regulatory machinery involved in frataxin
expression would aid in the identification of drugs or therapies
directed at restoring frataxin protein levels in Friedreich ataxia
patient tissues.
In this study, we used bioinformatic and molecular techniques
to identify two transcription factors, SRF and TFAP2, which
directly bind to the promoter region of the FXN gene. TFAP2 up-
regulated frataxin mRNA expression in several cell lines, whereas
SRF showed cell-line specific influences on frataxin expression.
Finally, over-expression of either transcription factor in Friedreich
ataxia patient-derived lymphoblasts or cell lines significantly
increased frataxin mRNA levels. Identification and further
characterization of these two new factors involved in frataxin
expression may aid in the development of new therapeutic avenues
for the treatment of Friedreich ataxia.
Results
In previous work we observed significant decreases in frataxin
mRNA levels in multiple human cell lines as well as primary
human fibroblasts and lymphoblasts derived from Friedreich
ataxia patients and controls, when treated with the iron chelator
desferrioxamine (DFO) [21]. These data suggested that one or
more regulatory elements might modulate transcription of frataxin
under varying metabolic conditions such as iron starvation. We
initiated the current study by using Genomatix software (www.
genomatix.de) to identify putative transcription factor binding sites
within the promoter that might serve as transcriptional regulatory
elements of the FXN gene. Although the FXN promoter region was
reported to extend at least 1255 bp upstream of the translation
start site (AUG) [22], in vitro experiments suggested that more than
60% of FXN promoter activity is conferred by the first 221 bp of
this upstream sequence [22]. We chose to pursue putative SRF
(serum response factor), TFAP2 (transcription factor AP2), and
SP1 binding sites within this 221 bp region due to a high matrix
similarity score of greater than 0.95 for these sequences
(Figure 1A). SRF binds to sequences known as serum response
elements, and is a member of the MADS (MCM1, Agamous,
Deficiens, and ARF) box superfamily of transcription factors that
can stimulate cell proliferation and differentiation [23]. TFAP2 is a
developmentally regulated, retinoic-acid inducible transcriptional
activator [24], while SP1 is a ubiquitously expressed factor that
interacts with numerous other transcription regulators involved in
many pathways (e.g., HIV-1 Tat, P53, RNAPII, EGR1, TFAP2)
[25,26]. Notably, the SRF and TFAP2 binding sites were found
within-, and immediately downstream of one of the few regions of
the FXN promoter that shows significant sequence similarity
between rodents and primates due to the presence of an L2
retrotransposon-like sequence [22].
To test whether SRF, TFAP2 or SP1 bind to the predicted FXN
promoter sequence elements defined above, chromatin immuno-
precipitation (ChIP) was performed using anti-SRF, TFAP2, and
SP1 primary antibodies, and qRT-PCR was used to quantify the
degree of transcription factor binding in the FXN promoter region.
Robust SRF and TFAP2 binding was observed in HEK293 cells
using several qRT-PCR primer sets (Figure 1B) encompassing the
promoter region of FXN, while binding of SP1 was found to be far
weaker than that of SRF or TFAP2 (Figure 1C). Similar results
were obtained for each primer set (Figure 1C, lower panel) and
comparable results were also obtained using K562 erythroleuke-
mia cells (not shown).
Next, in vitro electrophoretic mobility shift assays (EMSA) were
carried out to assess the binding of nuclear proteins to synthetic
dsDNA oligonucleotides encoding the putative TFAP2 and SRF
sequences found in the FXN promoter. In vitro binding of nuclear
proteins to the TFAP2 and SRF sequences was observed
(Figure 2A, 2B). Moreover, when antibodies raised against either
TFAP2 or SRF were included in the reactions, a ‘supershift’ was
observed (Figure 2A lane 8, 9, 10 and 2B lane 9, 10, 12),
suggesting formation of specific complexes between SRF or
TFAP2 and the respective antibodies, resulting in altered mobility
within the gel. These results strongly suggest that both SRF and
TFAP2 can bind to specific sequences within the promoter region
of the FXN gene.
Transcriptional regulatory elements have previously been
identified within the first intron of several genes [27,28,29,30].
Recently a region immediately upstream of the intronic GAA
expansion which was reported to be important for maximal
frataxin expression [15]. Further experiments showed that
expansion of the GAA repeats leads to changes in DNA
methylation and chromatin structure in this region of the FXN
gene [15]. Accordingly, we analyzed the region immediately
downstream of exon 1 using Genomatix software, and found a
putative EGR3 transcription factor binding site in this intronic
region (Figure 3A). To investigate whether this putative EGR3
binding site and the identified SRF and TFAP2-binding sites are
involved in transcription of frataxin, we generated four luciferase
reporter constructs. The first two constructs contained promoter
fragments that extended 558-bp (construct I) or 228-bp (construct
II) 59 of the start codon AUG linked to the luciferase gene; the
latter two (constructs III and IV) contained the same promoter
regions as construct I and II, respectively, but they also contained
part of the first intron including the proposed EGR3 binding site
(GCGCCGCGCACGCCGGG) (Figure 3A, dotted square). The
insert sizes were 1030-bp (III) and 650-bp (IV), separately.
Luciferase activity from constructs III and IV was substantially
higher than activity measured from constructs I and II (Figure 3A,
bottom panel), suggesting that the intronic region downstream of
exon 1 is important for transcription of the FXN gene.
We next used the luciferase assay to probe promoter activity of
variants of the above constructs in which the putative binding sites
for SRF, TFAP2, or EGR3 were altered. Mutation of either the
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dramatically decreased luciferase activity in three distinct cell
lines (Figure 3B). In contrast, minimal decreases in luciferase
activity were observed following mutagenesis of the SRF or
TFAP2 binding sites in constructs I and II (not shown), which lack
the intronic sequence downstream of exon 1 that is included in
construct IV. Interestingly, mutagenesis of the EGR3 binding site
in the FXN intronic sequence in construct IV had dramatically
different effects on luciferase expression depending on the cell lines
tested, causing severe, mild, or no significant effect on the
promoter activities in K562, SH SY5Y, and HEK293 cells,
respectively. Taken together, these results further suggest that SRF
and TFAP2 are transcription factors important for frataxin
expression, and the intronic sequence downstream of exon 1
which contains a putative EGR3 binding site is required for full
expression of frataxin.
Previously, we demonstrated that frataxin protein and mRNA
transcript levels are altered by perturbations in cellular iron status
brought on by treatment with the iron chelator DFO [21]. To test
whether iron-mediated changes in frataxin transcript levels might
be related to altered expression of either SRF or TFAP2, we
treated HEK293 and SH SY5Y cells with DFO and measured
mRNA levels of SRF and TFAP2 by qRT-PCR. While no
significant change in SRF mRNA levels was observed in iron-
depleted (+DFO) versus iron-replete (-DFO) cells, TFAP2 mRNA
levels were significantly decreased by iron depletion in both
HEK293 and SH SY5Y cells (Figure 4A). Frataxin mRNA levels
were also decreased by DFO treatment in HEK293 cells (as
reported previously [21]), but not in SH SY5Y cells (Figure 4A).
These data suggest that iron-mediated alterations in TFAP2
expression levels might influence frataxin mRNA expression
during cellular iron deficiency.
We also checked the mRNA expression levels of SRF, TFAP2,
and EGR3 in lymphoblasts derived from an Friedreich ataxia
patient (GM16214) and from a healthy control (GM16215). We
found that EGR3 expression was very low, while TFAP2
expression was undetectable (not shown). As expected, frataxin
mRNA levels were reduced in the Friedreich ataxia patient
lymphoblasts as compared to the control lymphoblasts, while SRF
mRNA expression levels were only moderately different between
the two cell lines (Figure 4B). Finally, a ChIP experiment revealed
that SRF occupancy of the FXN promoter was reduced in the
Friedreich ataxia patient lymphoblasts as compared to the control
lymphoblasts (Figure 4C).
The above data suggest that frataxin expression could be
enhanced by heterologous expression of SRF or TFAP2. To test
this hypothesis we over-expressed SRF or TFAP2 in SH SY5Y
cells, HEK293 cells, and in lymphoblasts obtained from an
Figure 1. Transcription factors SRF and TFAP2 bind to the FXN gene promoter region in vivo. (A) Sequence of 59-end of the human FXN
gene. Sequences are color-coded: intronic sequences in green, exon 1 and exon 2 in black. Putative transcription factor binding sites identified by
Genomatix analysis are annotated in bold black for SRF, in bold blue for TFAP2, in bold red for SP1, and in bold pink for EGR3. Start codon (AUG) in
exon 1 is in bold black. (B) Schematic diagram of human FXN promoter region showing the location of the putative regulatory sequences. Black-filled
square: SRF binding site; blue-filled square: TFAP2 binding site; red-filled square: SP1 binding site; pink-filled square: EGR3 binding site. Primers used
in the ChIP assays are designated as: P189, P195, P204, P205, P206, P364, and P365. (C) Binding of SRF and TFAP2 to the FXN promoter in vivo was
quantified by chromatin immunoprecipitation (ChIP) and quantitative real-time PCR (qRT-PCR). The upper panel is the quantification of FXN promoter
chromatin, immunoprecipitated using antibodies raised against SRF, TFAP2, and SP1. Three pairs of primers flanking the putative binding sites of
these transcription factors were used for the qPCR analysis. The lower panel shows the end-products of the qPCR reactions separated by agarose gel
electrophoresis. Primers specific for human FXN intron 4 were included as an internal negative control (data not shown).
doi:10.1371/journal.pone.0012286.g001
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of TFAP2 (A) and SRF (B) to the promoter region of FXN in vitro. Nuclear extracts from HEK293 cells were incubated with [c-
32P]-ATP labeled
oligonucleotides coding the predicted TFAP2 or SRF binding site on the FXN promoter region of interest for 1 hour at 4uC. The binding products were
resolved in native polyacrylamide gels (see MATERIALS AND METHODS). Specific competitor (non-radioactive oligonucleotide, so called cold probe,
10 mM) or non-specific competitor (poly(dI-dC), 0.5 mU/mL) was added to assess the specificity of the binding of SRF or TFAP2. Antibodies of TFAP2
(2 mg/ml) and SRF (0.5 mg/ml) were added for supershift, respectively. I: SRF antibody purchased from Santa Cruz Biotech.; II: SRF antibody purchased
from Active Motif. A: HEK293 cell nuclear extracts, prepared by the authors, B: Jurkat cell nuclear extracts, purchased from Active Motif (Carlsbad, CA).
doi:10.1371/journal.pone.0012286.g002
Figure 3. The SRF and TFAP2 binding sites in the FXN promoter are important for frataxin expression. (A) Luciferase analysis of a novel
intronic regulatory region of the FXN gene. The upper panel portrays the upstream region of the FXN gene including the exon 1 and 2 and intron 1.
Bottom panel: luciferase activity was measured in cells transfected with luciferase constructs containing truncated FXN promoter fragments
containing the SRF and TFAP2 binding sites. Filled square: SRF binding site; open square: TFAP2 binding site; dotted square: EGR3 binding site. The
four luciferase constructs are designated as I, II, III, IV (see MATERIALS AND METHODS). (B) Mutation of the SRF and TFAP2 binding sites in the FXN
promoter dramatically decreased luciferase activity driven from FXN promoter fragment IV. Mutation of the predicted EGR3 transcription factor
binding site in intronic sequence of the FXN gene showed cell line-specific effects on transcriptional activity. Three separate experiments were carried
out. For each experiment, duplicate transfections were performed. Error bars represent the standard deviation.
doi:10.1371/journal.pone.0012286.g003
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qRT-PCR was performed to assess changes in cellular frataxin
mRNA levels following transfection (Figure 5). First, we performed
in vitro translation to verify that our plasmid constructs expressed
SRF and TFAP2 protein products of the correct size (Figure 5A).
SRF and TFAP2 mRNA levels were found to be more than 100-
fold higher in cells transfected with plasmids pcDNA-SRF or
pcDNA-TFAP2 than in control cells transfected with an empty
plasmid control, pcDNA3.1(-) (data not shown). Over-expression
of SRF in HEK293, but not SH-SY5Y cells resulted in
significantly elevated frataxin mRNA levels, while over-expression
of TFAP2 in either cell line resulted in modest increases in frataxin
mRNA levels (Figure 5B). Strikingly, over-expression of either
TFAP2 or SRF in Friedreich ataxia patient lymphoblasts resulted
in significant increases in frataxin mRNA levels, while over-
expression of either transcription factor in control lymphoblasts
had no significant effect on frataxin mRNA levels (Figure 5C).
Finally, we measured frataxin protein levels in HEK293 cells after
transfection with either SRF or TFAP2. Consistent with the
changes in frataxin mRNA levels observed in these cells
(Figure 5B), western blots demonstrated that frataxin protein
levels were also increased (Figure 5D). Together, these results
suggest that frataxin expression levels can be influenced by both
SRF and TFAP2 expression in a variety of cell types.
Discussion
Deficiency of the frataxin protein is the primary molecular
defect in Friedreich ataxia disease. Frataxin levels in Friedreich
ataxia patients vary from between 5% and 30% of normal levels,
while healthy heterozygous carriers typically express more than
50% of normal frataxin levels [31,32,33]. Thus, it has been
suggested that restoration of frataxin gene expression levels in
Friedreich ataxia patients to levels observed in heterozygotes may
substantially slow disease progression. Characterization of the
regulatory elements controlling frataxin expression is critical in the
development of therapies directed at restoring frataxin expression
levels in Friedreich ataxia patients. In this study we identified two
transcription factors, SRF and TFAP2, which directly bind the
promoter region of the human FXN gene and alter frataxin mRNA
and protein levels. Over-expression of either of these two
transcription factors led to a significant increase in frataxin
mRNA levels in Friedreich ataxia patient lymphoblasts. Further-
more, frataxin protein levels were increased following over-
expression of SRF or TFAP2 in HEK293 cells. Thus, we conclude
that transcription factors SRF and TFAP2 directly influence
frataxin expression.
We previously demonstrated that cells derived from Friedreich
ataxia patients show signs of cytosolic iron deficiency, and that
Figure 4. Cellular iron depletion decreases frataxin expression. (A) Iron depletion decreases frataxin and TFAP2 mRNA levels in tested cells.
qRT-PCR was performed to quantify the mRNA levels of frataxin, SRF, and TFAP2 in SHSY5Y and HEK293 cells following treatment with 30 mM DFO for
48 hours. GAPDH was used as an internal control. Three separate experiments were carried out. For each experiment, duplicate iron treatment was
performed. The error bars represent standard deviation. Statistical analysis was performed using the Student’s t-test: **: r,0.001. (B) mRNA levels of
SRF and frataxin in lymphoblasts derived from patient (GM16214) and healthy control (GM16215). qRT-PCR was performed to quantify the mRNA
levels of frataxin and SRF with the total RNA isolated from patient and control. (C) Binding of SRF to the FXN promoter is dramatically decreased in
patient lymphoblasts. ChIP assays were conducted as described in Figure 1. The relative expression level in the patient cells is normalized to the
healthy control cells, which are set at 1.
doi:10.1371/journal.pone.0012286.g004
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induction of iron deficiency [21]. Here we have demonstrated that
mRNA levels of the transcription factor TFAP2, but not SRF, are
also regulated by iron in HEK293 cells. In affected tissues of
Friedreich ataxia patients, cytosolic iron depletion brought on by
decreased frataxin expression due to expansion of the GAA repeat
might result in decreased expression of TFAP2, resulting in an
even further reduction in frataxin expression. Unexpectedly,
overexpression of TFAP2 did not significantly increase mRNA
levels of frataxin in SH-SY5Y, HEK293, or lymphoblasts derived
from healthy control individuals. However, frataxin expression
levels were significantly enhanced by TFAP2 over-expression in
the Friedreich ataxia patient lymphoblast cell line. These effects
may be a result of different levels of occupancy of endogenous
TFAP2 on the putative TFAP2 binding site in the frataxin
promoter. Additionally, the TFAP2 family of transcription factors
is composed of five distinct gene products in humans (AP-2a, AP-
2b, AP-2x, AP-2d, and AP-2e), which can heterodimerize and
elicit tissue-specific transcriptional regulatory effects [24]. There-
fore, heterologous expression of additional TFAP2 family
members may be needed in order to see positive effects on
frataxin expression in all cell types utilized in this study.
Many genes contain intronic regulatory sequences that are
important for gene expression [34,35]. Bisulfite sequence
mapping of the region immediately upstream of GAA repeats
within FXN intron 1 (724 bp) identified sequences that enhance
FXN promoter activity [15]. However, this prior study did not
address the function of upstream sequences found immediately
following exon 1 (530 bp away from the 724 bp fragment). We
observed diminished luciferase activity in FXN promoter
constructs that lack this intronic region (Figure 3A; constructs I
and II), which contains a predicted consensus binding site for the
EGR3 transcriptional regulator. Since distinct band shift patterns
were observed in further EMSA experiments performed with
nuclear extracts from K562 and SH SY5Y cells (data not shown),
we may speculate that SRF and TFAP2 interact with other
regulatory elements to modulate frataxin expression in a cell-type
dependent manner. EGR3 is a good candidate co-regulator, since
mutagenesis of the predicted EGR3 binding site in our luciferase
experiments resulted in variable enhancer effects in the different
cell lines that were tested (Figure 3B). Interestingly, EGR3-
deficient mice exhibit several neuromuscular defects including
gait ataxia and scoliosis [36], symptoms which resemble those
exhibited by Friedreich ataxia patients. Moreover, EGR1 and
EGR3 double knockout mice displayed decreased frataxin
mRNA levels (57.3% of control) in thymocytes [37], indi-
cating that loss of EGR1/3 can transcriptionally alter frataxin
expression in vivo.
Figure 5. Overexpression of SRF or TFAP2 enhances frataxin expression in HEK293 cells and Friedreich ataxia patient
lymphoblasts. (A) In order to assess the effect of over-expression of SRF or TFAP2 on frataxin expression, plasmids pcDNA-SRF and pcDNA-AP2
were constructed and the correct sizes of the translation products of the cloned SRF and TFAP2 cDNA were verified by in vitro translation with [
35S]-
labeled methionine. The plasmid constructs were then transfected into HEK293 or SH SY5Y cells (B), or lymphoblasts (C) derived from healthy
individuals (GM15799, GM16215) or Friedreich ataxia patients (GM16179, GM16214), and frataxin mRNA levels were measured by qRT-PCR (see
MATERIALS and METHODS). Empty plasmid pcDNA3.1(-) was used as a control for comparison. The results from two different experiments were
similar; the data presented here are average values from the two experiments. Levels of mature frataxin protein were determined by western blot (D).
A representative western blot is shown here for HEK293 cells. Three separate experiments were carried out, and for each experiment two
transfections per sample were performed. Statistical analysis was performed using the Student’s t-test: *: r,0.05; **: r,0.001.
doi:10.1371/journal.pone.0012286.g005
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factors, SRF and TFAP2, which can directly bind sequences in the
promoter of the human FXN gene, likely enhancing frataxin
expression. Expression of recombinant transcription factors SRF
or TFAP2 in two distinct human cell lines, as well as in Friedreich
ataxia patient lymphoblasts, resulted in increased frataxin mRNA
levels. These results demonstrate that frataxin expression can be
enhanced by these two key transcription factors. Potential
interaction partners of SRF and TFAP2, including EGR3, should
be further explored to shed light on the regulatory network
governing frataxin expression, as well as the tissue-specific
pathology of Friedreich ataxia disease.
Materials and Methods
Cell culture and transfection
Cell lines HEK293, K562, and SH SY5Y were purchased from
ATCC (Manassas, VA). Lymphoblasts derived from healthy
controls (GM15799, GM16215) and Friedreich ataxia patients
(GM16197, GM16214) were obtained from the Coriell Cell
Repository (Camden, NJ). HEK293 cells were grown in alpha-
modified MEM medium (Sigma, St. Louis, MO), SH SY5Y in
DMEM/F-12 medium (Invitrogen, Carlsbad, CA), and lympho-
blasts in RPMI 1640 medium (Invitrogen), all supplemented with
10% fetal calf serum and 2 mM glutamine. For transfection of
HEK293 and SH SY5Y cells, Fugene 6 (Roche, Indianapolis, IN)
was used according to the supplier’s manuals. For transfection of
lymphoblast cells, cell line Nucleofector Kit V (Lonza, cat# VCA-
1003, Gaithersburg, MD) was used.
DNA constructs
Plasmid constructs expressing the transcription factors were
generated with primers 59- tttCTCGAGatgttaccgacccaagctgg-39
and 59-ggggAAGCTTtcattcactcttggtgctgt-39 for SRF, primers 59-
ttCTCGAGccagactcttcgcagatgtt-39 and 59- ccAAGCTTtcac-
tttctgtgcttctcctc-39 for TFAP2, and primers 59- ccCTCGAGat-
gagcgaccaagatcactc-39 and 59-ccAAGCTTtcagaagccattgccactga -
39 for SP1. The PCR products were cloned into plasmid
pcDNA3.1(-) with XhoI and HindIII restriction sites. The plasmids
for luciferase assay were constructed by cloning PCR products
(558 bp (construct I), 228 bp (II), 980 bp (III), and 650 bp (IV)),
covering the direct upstream of human FXN gene coding sequence
or lengthening into the first intron 257 bp of FXN gene, into
pGL4.10 (Promega, Madison, WI). Site-directed mutagenesis was
carried out by using primers 59- GCAGGCTCTGGAT-
TCGCGTTAAATGCACG -39 and 59- CGTGCATTTAACG-
CGAATCCAGAGCCTGC -39, or primers 59- CTGCTC-
CCCCACAGAAGAGTAAATGCAACCAGTGGCCACCAGG
-39 and 59- CCTGGTGGCCACTGGTTGCATTTACTCTT-
CTGTGGGGGAGCAG-39, or primers 59- CGCAGCACCA-
GCGCTGGAAAACAAAGCGGAGCGGGCGGCAGA-39 and
59- TCTGCCGCCCGCTCCGCTTTGTTTTCCAGCGCTG-
GTGCTGCG-39, or primers 59- GAGGCGCCGCGCTAT-
TCGGGGTCGCTC-39 and 59- GAGCGACCCCGAATAG-
CGCGGCGCCTC -39, which contained the mutated predicted
binding sites of SRF, TFAP2, SP1, or EGR3, respectively,
following the supplier’s instructions (Stratagene, La Jolla, CA).
Plasmid DNA was isolated with Qiagen miniprep or midiprep kits
(Valencia, CA) as needed.
Chromatin immunoprecipitation (ChIP)
ChIP was conducted with Magna ChIP
TM G Kit (Millipore,
cat#MAGNA0002, Billerica, MA) following the manufacturer’s
instruction. Briefly, cells were treated with formaldehyde (1%) for
10 min to crosslink the chromatin with the potential transcription
factors. Harvested cells were sonicated to shear chromosomal
DNA to an average length between 200 to 600 base pairs. Isolated
chromatin was incubated with the proper primary antibody
against human transcription factor SRF, TFAP2, SP1, or EGR3
(Santa Cruz Biotech. Inc., Santa Cruz, CA). After a series of
wash steps, the chromatin was eluted for further real-time PCR
analysis.
Electrophoretic mobility shift assays (EMSAs)
DNA gel-shifts were carried out with a double-stranded
oligonucleotide 201 (oligo 201) 59- CGTGCATTTAACAA-
AAATGGAGAGCCTGCTTT-39 for transcription factor SRF,
oligo 202 59- CAGAAGAGTGCCTGCGGCCAGTGGCCA-
CCA-39 for transcription factor TFAP2, oligo 203 59- CCA-
GCGCTGGAGGGCGGAGCGGGCGGCAGA-39 for transcrip-
tion factor SP1 in 20 ml of 25 mM Hepes (pH 7.5), 40 mM NaCl,
1 mM EDTA, 4 mM DTT, and 10% glycerol for 1 hour at 4uC,
after labeling the double stranded oligonucleotide with [c-P
32]-
ATP (Perkin Elmer, cat#NEG035C, Waltham, MA). Nuclear
extracts were prepared from HEK293 cells using NE-PER
Nuclear Extraction Reagents (Pierce, Rockford, IL, USA)
according to the supplier’s instructions. For assessment of binding
specificity, poly(dI-dC) (Sigma, cat#P4925) was added to each
reaction, from a stock concentration of 0.5 mU/ml. Antibody
supershift reactions were performed following manufacturers
instructions (Active Motif, Carlsbad, CA). Antibodies of SRF
and TFAP2 and Jurkat nuclear extract for supershift were
purchase from Active Motif. Following 5% native polyacrylamide
gel electrophoresis (29:1, acrylamide:bisacrylamide) with Tris-
Borate-EDTA (1X TBE) casting and running buffer, gels were
dried and exposed to a phosphor screen, which was visualized
using a Typhoon Imager (GE, Piscataway, NJ).
Real-Time PCR
The comparative Ct method with SYBR Green was conducted
with the ABI 7000 Real-Time PCR System (Applied Biosystems,
Foster City, CA). For human FXN gene detection, the following
primers were used: 59-CCTTGCAGACAAGCCATACA-39 and
59-CCACTGGATGGAGAAGATAG-39 [21]; for SRF, primer
249 59-AGAAGGCCTATGAGCTGTCC-39 and primer 250 59-
TTGCCGGTCTCACTGGTGAT-39; for TFAP2, primer 274
59-TCCAACAGCAATGCCGTCTC-39 and primer 275 59- GC-
CACCGTGACCTTGTACTT-39; for EGR3, primer 265 59-
GCCAGGACAACATCATTAGC-39 and primer 266 59-AG-
GTCGCCGCAGTTGGAGTA-39. Endogenous GAPDH was
used as an internal control with primers 59-TGCACCAC-
CAACTGCTTAGC-39 and 59-GGCATGGACTGTGGTCAT-
GAG-39 for normalization. Different primer combinations for
transcription factor binding sites in ChIP assays were primer 204
59- TTACACAAGGCATCCGTCTC-39 and primer 205 59-
GGAGCAGCTAGAGGTTAGAC-39; primer 206 59- GGTC-
TAACCTCTAGCTGCTC-39 and primer 195 59- TTTTT-
TAAGCTTCTGCTCCGGGTCTGCCGCCC-39; primer 189
59- ATTGGTACCACCAGGCTGCAGTCTCCCTT-39 and
primer 195; primer 364 59-TAAGTATCCGCGCCGGGAAC-
39 and primer 365 59-AATGCAACCGGGAGAACCAG-39 with
template DNA from isolated chromatin (see ChIP experiment) for
quantitative real-time PCR. A part of sequence of Human FXN
intron 4 was amplified as a ChIP negative internal control with
primers 59-AGGCCAAGGCCTGTGGATCA-39 and 59-
AGTGGCGCGATCTTGGCTCA-39.
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Proteins were resolved in 12% NUPAGE gels (Invitrogen, cat#
NP0342box) and transferred onto nitrocellulose membranes
(Invitrogen, cat# IB3010-01). Primary antibodies used were
rabbit anti-TFAP2 and anti-SP1 (Sant Cruz Biotech, Inc, Santa
Cruz, CA), mouse anti-SRF and anti-tubulin (Abcam, Cambridge,
MA), and mouse anti-frataxin (MitoScience, Eugene, Oregon).
The mature frataxin form (,14 kDa) was quantified for
comparison when needed. Western blot band intensities were
quantified using program ImageJ. Any change of the intensities
was compared with the controls, which value was set as 1.
Luciferase assay
The indicated plasmids derived from pGL4.10 [luc2] (Promega)
were co-transfected with pGL4.75 [hRluc/CMV] into HEK293,
K562, or SH SY5Y cells. Luciferase activities were measured with
Dual-LuciferaseH Reporter Assay System (Promega) by using
Veritas microplate luminometer (Turner Biosystems, Sunnyville,
CA). For control of transfection efficiency in each well, firefly
luciferase activity was normalized to Rellina luciferase activity.
Bioinformatic and statistical analysis
Online software Genomatix (http://www.genomatix.de) was
used to search the binding sites of putative transcription factors in
the promoter region of the human FXN gene. Other statistical
analyses in this study were performed using the Student’s t-test
(http://www.danielsoper.com/statcalc/).
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